CardioDx confronts tough reimbursement climate by touting cost-effective CAD test

CardioDx is touting the results of a new study that showed its Corus CAD molecular diagnostic test for obstructive coronary artery disease can help commercial health insurers save money. The Palo Alto, CA, outfit and 2012 Fierce 15 winner said that use of the test prior to referral for cardiac imaging leads to savings of 77 cents per member per month, or nearly $4.6 million for a health plan covering 500,000 adults. The reason: The test is designed to help assess whether the symptoms of stable, nondiabetic patients are due to obstructive coronary artery disease. Its use, the company said, saved money by reducing the number of patients who needed noninvasive cardiac imaging and invasive coronary angiography. Details are published in the journal Population Health Management. Making the money-saving pitch is smart for CardioDx, because it helps set the company apart in the emerging healthcare environment, where diagnostic tests have a harder time winning reimbursement unless they can show real savings plus a boost to the standard of care. Last November, CardioDx pulled its proposed IPO, citing poor market conditions. Release | Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.